Buy PCVX Ahead of VAX-31 Catalysts - Asymmetric Upside Into 1H 2027 Readouts
Vaxcyte (PCVX) is a Strong Buy from our desk into a run of pivotal readouts for VAX-31 and related programs. The shares have pulled back to $66.62 after a sharp run-up; positive Phase 3 / IPD efficacy data in the coming months would likely re-rate this name materially given its 31-valent coverage and recent validation in The Lancet. We lay out an a…